Bio-Rad Laboratories Deferred Revenue 2011-2026 | BIO

Deferred revenue is the amount of money or obligations that a company has received in advance for goods or services that have not yet been delivered or performed. In other words, it is income that has already been received but has not yet been recognized in accounting as revenue because the goods or services have not yet been transferred to the customer.

Features of the metric

Sources of future cash inflows
A high level of deferred revenue indicates that the company has secured future cash flows, which positively affects forecasts of its financial condition and stability.
Assessment of operational stability
Deferred revenue reflects demand for the company’s products or services and its ability to attract customers willing to pay in advance. It is one of the indicators of business stability and its competitive advantages.
Risks and obligations
Although deferred revenue indicates future inflows, it also represents obligations that the company must fulfill. If fulfilling these obligations is delayed or impossible, it can negatively impact reputation and financial results.
Analysis of liquidity and cash flow
Inflows in the form of deferred revenue improve the company’s current liquidity since the funds are already in the accounts. However, investors need to assess the ratio of deferred revenue to fulfilled obligations to understand the actual financial capabilities and risks.
Impact on company valuation
In fundamental analysis, deferred revenue is taken into account for accurate revenue and profit forecasting, especially in industries with long-term contracts or subscriptions (e.g., IT sector, services, manufacturing).

Annual Deferred Revenue Bio-Rad Laboratories

2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
47.8 M	51.1 M	52.2 M	50.9 M	42.5 M	33.7 M	26.9 M	28.2 M	31 M	29.7 M	26.7 M	26.4 M	26.3 M	24.3 M

All numbers in USD currency

Indicator range from annual reports

Maximum	Minimum	Average
52.2 M	24.3 M	35.6 M

Quarterly Deferred Revenue Bio-Rad Laboratories

2025-Q2	2025-Q1	2024-Q3	2024-Q2	2024-Q1	2023-Q3	2023-Q2	2023-Q1	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
54.4 M	53.8 M	48.9 M	52 M	55.1 M	49.1 M	53.7 M	56.9 M	52.2 M	58 M	-	59.3 M	50.9 M	47.9 M	47.5 M	48 M	42.5 M	42.5 M	42.5 M	42.5 M	33.7 M	33.7 M	33.7 M	-	26.9 M	-	-	-	28.2 M	-	-	-	31 M	-	-	-	29.7 M	-	-	-	26.7 M	-	-	-	26.4 M	-	-	-	26.3 M	-	-	-	24.3 M	-	-	-

All numbers in USD currency

Indicator range from quarterly reporting

Maximum	Minimum	Average
59.3 M	24.3 M	42.6 M

Deferred Revenue of other stocks in the Medical devices industry

Issuer	Deferred Revenue	Price	% 24h	Market Cap	Country
AxoGen AXGN	14 K	$ 31.63	2.03 %	$ 1.4 B	USA
Acutus Medical AFIB	401 K	-	-26.83 %	$ 2.62 M	USA
Boston Scientific Corporation BSX	306 M	$ 95.41	0.76 %	$ 140 B	USA
Abiomed ABMD	24.3 M	-	-	$ 17.2 B	USA
Allied Healthcare Products AHPI	563 K	-	3.58 %	$ 2.21 M	USA
GenMark Diagnostics, Inc. GNMK	508 K	-	-	$ 1.77 B	USA
Alphatec Holdings ATEC	10.5 M	$ 21.25	2.36 %	$ 3.04 B	USA
Apyx Medical Corporation APYX	500 K	$ 3.6	2.86 %	$ 125 M	USA
Cognyte Software Ltd. CGNT	127 M	$ 9.15	2.81 %	$ 657 M	Israel
Obalon Therapeutics, Inc. OBLN	424 K	-	-5.86 %	$ 30.6 M	USA
Apollo Endosurgery APEN	88 K	-	-	$ 475 M	USA
Conformis CFMS	215 K	-	-	$ 16.4 M	USA
BioSig Technologies BSGM	16 K	-	37.08 %	$ 85.7 M	USA
Bruker Corporation BRKR	438 M	$ 50.6	5.18 %	$ 7.54 K	USA
EDAP TMS S.A. EDAP	6.64 M	$ 3.48	2.35 %	$ 130 M	France
Cardiovascular Systems CSII	2.11 M	-	0.15 %	$ 844 M	USA
Cutera CUTR	10.4 M	-	-10.19 %	$ 1.99 M	USA
CryoLife, Inc. CRY	1.45 M	-	-4.14 %	$ 702 M	USA
Eargo EAR	621 K	-	-	$ 10.2 M	USA
Hancock Jaffe Laboratories, Inc. HJLI	33	-	-1.98 %	$ 98.3 M	USA
Itamar Medical Ltd. ITMR	732 K	-	0.03 %	$ 1.58 B	Israel
Second Sight Medical Products EYES	335 K	-	-0.97 %	$ 54.4 M	USA
Misonix, Inc. MSON	13.3 K	-	-	$ 462 M	USA
Dynatronics Corporation DYNT	150 K	-	14.99 %	$ 929 K	USA
Intersect ENT, Inc. XENT	137 K	-	-	$ 955 M	USA
InMode Ltd. INMD	11.9 M	$ 15.27	3.18 %	$ 1.21 B	Israel
IRadimed Corporation IRMD	2.26 M	$ 98.11	2.73 %	$ 1.24 B	USA
Align Technology ALGN	1.33 B	$ 160.18	2.66 %	$ 12 B	USA
Accuray Incorporated ARAY	82.3 M	$ 0.89	4.38 %	$ 91.5 M	USA
ClearPoint Neuro CLPT	2.12 M	$ 14.34	2.21 %	$ 388 M	USA
FONAR Corporation FONR	4.29 M	$ 18.52	0.03 %	$ 121 M	USA
LivaNova PLC LIVN	10.8 M	$ 63.29	4.37 %	$ 3.43 B	Britain
LENSAR LNSR	1.68 M	$ 11.32	-2.5 %	$ 130 M	USA
IRIDEX Corporation IRIX	2.4 M	$ 1.21	3.42 %	$ 19.5 M	USA
Globus Medical GMED	22.1 M	$ 90.81	4.02 %	$ 12.3 B	USA
Integra LifeSciences Holdings Corporation IART	10.5 M	$ 12.56	4.58 %	$ 967 M	USA
Aziyo Biologics AZYO	533 K	-	1.37 %	$ 20.5 M	USA
Establishment Labs Holdings ESTA	1.75 M	$ 65.25	-5.21 %	$ 1.84 B	Costa-rica